Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

604 clinical trials found

Clinical trials

MRTLE-OLE

An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04529954)

Currently recruiting

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma (NCT06478693)

Currently recruiting

Multisite

Inter-organ cross talk in heart failure: A multisite biomarker sampling study (ACTRN12621001725853)

Non fasting blood samples are collected during the patients clinically indicated right heart catheterisation procedure. Blood is taken from the coronary sinus, pulmonary, hepatic and renal vein and from an arterial site. An echocardiogram is performed if the patient has not had one within the past 3 months. A 6 WMT and QOL questionnaires, ECG may also be performed.

Currently recruiting

MY-PROMPT-2

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (ACTRN12622001199707p)

Currently recruiting

NADINA

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)

No longer recruiting

NADOM

NADOM trial – Neoadjuvant/ Adjuvant trial of Darovasertib in Ocular Melanoma (NCT05187884)

No longer recruiting

NAVAL-1

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (VT3996-202) (NCT05011058)

Currently recruiting

Nektar 23-358-05

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis (NCT06136741)

No longer recruiting

NeoFOL-R

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter Randomized, controlled trial (NeoFOL-R) (ACTRN12624000005550)

Currently recruiting

NIMBLE

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype (NCT04718389)

No longer recruiting

NIMBLE-AZD0466

A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419)

Currently recruiting

NIVO-LD

Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretroviral therapy (ART): NIVO-LD (NCT05187429)

Currently recruiting

NN9500-4656

Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial (NCT05016882)

Currently recruiting

NOTACS

Effect of Nasal High-Flow Oxygen Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled Trial (NCT05308719)

No longer recruiting

NVG-2089-201

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Currently recruiting

OASIS

A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species (NCT05101187)

Currently recruiting

OCEANIC AF

A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (NCT05643573)

No longer recruiting

OCEANIC-STROKE

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA (NCT05686070)

Currently recruiting

Olympia-1

A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untreated participants with Follicular Lymphoma. (NCT06091254)